Search Within

Gastrointestinal Oncology Service

  1. "2007"
Formats
  1. Journal Article (45)
  2. Meeting Abstract (34)
  3. Book Section (2)
  4. Book Whole (1)
Groups
  1. Department of Medicine (82)
  2. Solid Tumor Oncology Division (82)
  3. Center for Pancreatic Cancer Research (38)
  4. Biostatistics Service (21)
  5. Epidemiology and Biostatistics (21)
  6. Surgery (18)

More Groups

People
  1. Leonard Saltz (38)
  2. David Ilson (16)
  3. David Kelsen (16)
  4. Nancy Kemeny (14)
  5. Manish Shah (10)
  6. Marinela Capanu (9)

More People

Years
  1. 2007 (82)
Publications
  1. Journal of Clinical Oncology (40)
  2. Annals of Oncology (5)
  3. Annals of Surgical Oncology (3)
  4. Journal of the National Comprehensive Cancer Network (3)
  5. Cancer Investigation (2)
  6. Hematology/Oncology Clinics of North America (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (40)
  2. Elsevier Inc. (7)
  3. Oxford University Press (6)
  4. Elsevier Science, Inc. (4)
  5. Springer (4)
  6. Harborside Press (3)

More Publishers

Results (82)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of oral S-1 in combination with oxaliplatin (oxali) and bevacizumab (bev) in patients with advanced solid tumors
    Meeting Abstract

    Zhang, J.; Chung, K.; Zergebel, C.; Urrea, P.; Quinones, M.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
    Meeting Abstract

    Zhang, W.; Yang, D.; Capanu, M.; Hollywood, E.; Lue-Yat, M.; Borucka, E.; Azuma, M.; Gordon, M.; Saltz, L.; Lenz, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors
    Meeting Abstract

    Tse, A. N.; Carvajal, R.; Shah, M.; Dials, H.; Fogel, M.; O'Reilly, E.; Chung, K.; Maki, R.; Wu, N.; Egorin, M.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Predictors of a true complete response in colorectal liver metastases that disappear radiographically following chemotherapy
    Meeting Abstract

    Taylor, R. A.; White, R. R.; Kemeny, N.; Jarnagin, W. R.; DeMatteo, R. P.; Fong, Y.; Blumgart, L. H.; D'Angelica, M.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer
    Meeting Abstract

    Saltz, L.; Clarke, S.; Diaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T.; Cassidy, J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Volumetric 3D CT analysis - an early predictor of response to therapy
    Meeting Abstract

    Schwartz, L. H.; Curran, S.; Trocola, R.; Randazzo, J.; Ilson, D.; Kelsen, D.; Shah, M.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer (NCI 5917): FDG-PET/CT predicts patient outcome
    Meeting Abstract

    Shah, M. A.; Yeung, H.; Coit, D.; Trocola, R.; Ilson, D.; Randazzo, J.; Tang, L.; Brennan, M.; Divgi, C.; Kelsen, D. P.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Minimal residual local disease predicts improved survival after chemoradiotherapy in patients with squamous cell carcinoma of the esophagus
    Meeting Abstract

    Rizk, N. P.; Tang, L.; Park, B. J.; Flores, R.; Venkatraman, E.; Bains, M. S.; Ilson, D.; Minsky, B.; Rusch, V. W.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab 5mg/kg can be safely infused over 10 minutes
    Meeting Abstract

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V.; Hollywood, E.; Sklarin, N.; Muller, R.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [Pca]: SWOG S0205 study
    Meeting Abstract

    Philip, P. A.; Benedetti, J.; Fenoglio-Preiser, C.; Zalupski, M.; Lenz, H.; O'Reilly, E.; Wong, R.; Atkins, J.; Abruzzese, J.; Blanke, C.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save